In the world of healthcare M&A, I frequently encounter founders who are deeply attached to their businesses. This is especially common among younger healthcare entrepreneurs, who often view their companies as unstoppable growth engines uniquely positioned to scale perpetually. While this optimism is essential to building a successful business, it can sometimes blind founders to the inevitable cycles of the healthcare industry. This mindset often leads them to reject early offers, assuming that a better one is just around the corner. Many return months later with regret, realizing that the first offer was, in fact, the best one they could have received.
In this article, we’ll explore why founders in the healthcare M&A space should carefully consider early offers. We’ll discuss the importance of having an exit strategy, the value of working with a seasoned M&A advisor, and the flexibility required in negotiations. Additionally, we’ll review the “5 D’s” that can lead to unexpected exits and offer insights on how to evaluate offers effectively in the healthcare sector.
Healthcare M&A Reality Check: Unanticipated Challenges in the Industry
Healthcare entrepreneurs often view their businesses with an optimistic lens, especially younger founders who believe their companies are immune to downturns. This confidence, while valuable, can sometimes prevent founders from seeing the larger picture. Healthcare businesses are not insulated from external forces—macroeconomic factors, regulatory changes, competitive dynamics, and technological advancements can all impact their value.
Consider these healthcare-specific scenarios:
Macroeconomic Shifts: A market downturn can drastically reduce valuations, even for profitable healthcare companies. For instance, during the 2008 financial crisis, many solid businesses across sectors saw their values plummet. Waiting for a better offer in a fluctuating market can mean missing out entirely.
Regulatory Changes: The healthcare sector is heavily regulated, and policy changes can significantly impact a business’s operations and revenue. A healthcare company that receives an offer before a regulatory shift may find that this offer represents its peak value.
Competitive Pressures: New healthcare providers and startups frequently enter the market, offering innovative solutions or competitive pricing, which can erode an established company’s market share. A strong offer today may not be available tomorrow if the competitive landscape shifts.
Technological Advancements: In healthcare, technology is advancing rapidly, and new innovations can quickly render existing products or services obsolete. If a competitor develops a better product, the value of your healthcare company could decrease overnight.
These challenges align with Porter’s Five Forces—the competitive factors that influence industry profitability. Porter’s Five Forces include competitive rivalry, bargaining power of suppliers, bargaining power of buyers, threat of new entrants, and threat of substitutes. In healthcare M&A, each of these forces can significantly affect a business’s standing and profitability. Recognizing these forces helps founders understand why strategic timing is essential and why seizing favorable conditions is often the best course of action.
The 5 D’s That Lead to Unexpected Exits in Healthcare M&A
In healthcare M&A, certain life events can unexpectedly force even the most committed founder to consider an early exit. These are the “5 D’s”: Disability, Divorce, Distress, Disruption, and Death. Any one of these can impact a founder’s ability to lead and compel them to reevaluate their plans.
Disability: Healthcare founders often play a central role in their business. If a founder becomes disabled due to illness or injury, their absence can significantly impact operations, growth, and overall stability. Planning for an exit or transfer in advance helps ensure the business’s resilience and value remain intact, even if a disability disrupts the founder’s involvement.
Divorce: Divorce can bring personal and financial strain, impacting both the founder and the business. In many cases, assets are divided, including business shares, which can lead to ownership disputes or liquidity needs, making an exit more immediate and complex.
Distress: In healthcare, distress often involves financial strain, cash flow issues, or increasing operational costs. When a business experiences distress, it may need a quick exit to avoid a steep decline in value. Considering exit options during times of distress, especially when the company still holds market appeal, can protect against larger losses.
Disruption: The healthcare industry is highly susceptible to external disruptions such as technological advances, regulatory changes, or shifts in consumer behavior. These changes can erode a business’s market position, making an exit at peak value crucial before these disruptions impact the company’s worth.
Death: Although challenging to discuss, the sudden death of a founder or key stakeholder can destabilize a healthcare company, impacting leadership continuity, patient relationships, and investor confidence. A well-planned exit strategy ensures the business can transition smoothly or retain its value even after a founder’s passing.
The takeaway? Founders in healthcare M&A should prepare for any eventuality by maintaining an open mind when offers come in. Life circumstances, no matter how unforeseen, can significantly alter even the best-laid plans.
Why an Exit Strategy and M&A Advisor Are Essential in Healthcare M&A
Creating an exit strategy early on is one of the smartest moves a healthcare founder can make. Think of it as insurance—it’s there if you need it, and even if you don’t, it provides peace of mind and strategic direction. An exit strategy allows founders to approach offers with confidence, knowing their business is prepared for a seamless transition when the time comes.
In healthcare M&A, a specialized M&A advisor is invaluable. Advisors help founders navigate the complexities of evaluating offers, understanding market timing, and positioning the business for maximum appeal to potential buyers. Their objective, seasoned perspective helps avoid common pitfalls, such as overestimating a business’s resilience in a highly regulated and competitive industry.
Key Factors to Consider When Evaluating a Healthcare M&A Offer
When an offer arrives, several critical factors should be evaluated, especially in the healthcare sector. A checklist can help prevent founders from being swayed by emotion or a desire to “hold out” for an ideal price. Here are key elements to consider:
Market Conditions: Timing is crucial in healthcare M&A. A strong market generally means higher valuations, but market conditions can change quickly. By assessing the broader economic landscape with an advisor, founders can gauge the offer’s long-term viability.
Company Stability and Growth Potential: Evaluate the business’s current performance and future growth honestly. Is the growth rate sustainable? What are the potential risks? If the business’s value is at its peak, waiting could mean a dip in valuation.
Buyer’s Intentions and Reputation: Sometimes, the best offer isn’t the highest bid. A buyer’s intentions, reputation, and alignment with the company’s mission can be just as important as the price. A committed, mission-aligned buyer may lead to smoother negotiations and a positive legacy for the healthcare brand.
Timing and Urgency: Business timing is critical. Will the healthcare company still hold this valuation if the founder waits another year? How long will current demand remain high? Urgency can prompt founders to capitalize on favorable conditions.
Alignment with Personal and Professional Goals: Does selling align with the founder’s life stage? Are there other personal or professional goals they wish to pursue outside of the healthcare business?
Flexibility: The Key to Successful Negotiation in Healthcare M&A
In healthcare M&A, rigidity can be a disadvantage. Founders may envision a “perfect” offer, but offers rarely meet every criterion. Remaining open to negotiation and compromise is essential, especially when working with seasoned buyers who may bring creative financing or counteroffers.
Flexibility also applies to timing. Just because an offer arrives early doesn’t mean it’s premature. In healthcare M&A, offers often come because the business is at an ideal stage for acquisition. Being adaptable sets the stage for a successful outcome, whatever form it may take.
Conclusion: Embrace the First Offer as a Strong Contender in Healthcare M&A
Receiving an offer is both a compliment and an opportunity. Viewing the first offer as a genuine option rather than dismissing it outright is a smart approach. The healthcare industry is unpredictable, with regulatory changes and market shifts that can affect valuations. Often, those who wait for an idealized “better” offer end up regretting it as circumstances shift.
With a balanced approach, founders can evaluate early offers within the context of market conditions, company performance, and personal goals. With the support of a healthcare M&A advisor and a strong exit strategy, founders empower themselves to make the best possible decision, ensuring their journey—whether it ends with the first offer or not—is ultimately successful.
Dr. Allen Nazeri, aka "Dr. Allen," boasts over 30 years of global experience as a healthcare entrepreneur. He is the Managing Director at American Healthcare Capital and Managing Partner at PRIME exits. Dr. Allen provides strategic growth consulting to leadership teams of both privately held and publicly listed companies, ensuring their preparedness for successful exits.
He holds a Dental Degree from Creighton University and an MBA in M&A and Investment Banking from the University of Bedfordshire. Dr. Allen is the author of "Value Engineering: Strategies to 10X the Value of Your Clinic and Dominate the Market!" and the brand new book "Selling Your Healthcare Company at a Premium". Dr. Allen offers a free valuation to business owners ready for a partial or complete exit strategy. Dr. Allen collaborates with strategic buyers, private equity firms, and institutional investors, taking direct accountability for the annual successful sell-side representation of nearly $750M in enterprise value.
To have a confidential discussion about your company and receive a free valuation, please email Allen@ahcteam.com or Allen@ahcpexits.com
You can now communicate with Dr. Allen's clone https://www.delphi.ai/drallen
Comments